As Low As $0
Out of Pocket
XEOMIN Mechanism of Action

The Science Behind XEOMIN

XEOMIN Mechanism of Action

Clostridium botulinum is a naturally occurring neuromodulator. Manufacturers use a selected strain, bred biologically in optimal conditions, to produce therapeutic botulinum toxin products1

XEOMIN is a botulinum toxin type A that blocks transmission at the neuromuscular junction by inhibiting the release of acetylcholine (ACh) from peripheral cholinergic nerve endings1

In both muscles and glands, impulse transmission is re-established by the formation of new nerve ends1

XEOMIN Mechanism of Action Video

Purifying Botulinum Toxin Type A Into XEOMIN

XTRACT TechnologyTM is the only state-of-the-art manufacturing process that uniquely purifies the molecule removing the unnecessary proteins, leaving just the active therapeutic component.*

Neurotoxin separated from accessory proteins Neurotoxin separated from accessory proteins

*The direct impact of the non-therapeutic proteins on long term safety or efficacy has not been established. Information about the unique XEOMIN manufacturing process and the properties of incobotulinumtoxinA is not intended to imply superiority over other botulinum toxin type A products.

XEOMIN Manufacturing Video

The XEOMIN Difference

XEOMIN is the only clinically proven neuromodulator uniquely purified to remove
unnecessary proteins*

The molecular weight of XEOMIN is 150 kDa because the proprietary manufacturing process of XEOMIN isolates the active neuromodulator from accessory proteins and reduces the proteins. As a result, XEOMIN is formulated to have high biological activity with a low protein load1-3

Molecular weights of botulinum toxins less with XEOMIN

The potency Units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products.


  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2019.
  2. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-1768.
  3. Dressler D. Botulinum toxin drugs: future developments. J Neural Transm. 2008;115(4):575-577.